Mechanisms and treatment of anemia in chronic heart failure.

Anemia is highly prevalent in patients with chronic heart failure (HF) and is associated with poor clinical outcomes. Multiple mechanisms contribute to anemia in chronic HF, and subnormal compensatory rise in endogenous erythropoietin levels in response to anemia is one contributory factor. Randomized trials with recombinant human erythropoietin therapy in anemic patients with chronic kidney disease and concomitant heart disease have demonstrated a reduction in left ventricular hypertrophy but variable effects on clinical outcome. Preliminary clinical trials in anemic patients with chronic HF demonstrate that erythropoietin therapy is well tolerated and associated with short-term clinical improvement. The optimum target hemoglobin, erythropoietic agent, and dosing regimen, and the role of iron supplementation in patients with chronic HF, are not known. Additional studies are needed to determine the safety and efficacy of long-term erythropoietic therapy in chronic HF patients.

[1]  H. Eiskjær,et al.  Elevated level of erythropoietin in congestive heart failure Relationship to renal perfusion and plasma renin , 1993, Journal of internal medicine.

[2]  A. D. Black,et al.  Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. , 2003, Biochemical and biophysical research communications.

[3]  G. Semenza,et al.  Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia‐Reperfusion Injury , 2003, Circulation.

[4]  J. Fisher,et al.  Erythropoietin: Physiology and Pharmacology Update 2 , 2003, Experimental biology and medicine.

[5]  F. Locatelli,et al.  Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  D. Mann,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[7]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[8]  A. Christensson,et al.  A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Y. Asano,et al.  Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. , 2000, Kidney international.

[10]  I. Macdougall,et al.  Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  A. Kurtz,et al.  Oxygen sensing in the kidney and its relation to erythropoietin production. , 1989, Annual review of physiology.

[12]  J. Adamson,et al.  IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  M. Gassmann,et al.  Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. , 2001, Blood.

[14]  M. Hori,et al.  Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  D. Schwartz,et al.  The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  K. Kuck,et al.  Erythropoietin and VEGF exhibit equal angiogenic potential. , 2002, Microvascular research.

[17]  M. Iruela-Arispe,et al.  Inactivation of erythropoietin leads to defects in cardiac morphogenesis. , 1999, Development.

[18]  A. Levin,et al.  Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. , 2002, Kidney international. Supplement.

[19]  M. Rothstein,et al.  Effect of recombinant human erythropoietin on endothelial cell apoptosis. , 1999, Kidney international.

[20]  I. Pham,et al.  Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics , 2001, European journal of clinical investigation.

[21]  C. Winearls.  Recombinant human erythropoietin: 10 years of clinical experience. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  A. Saraste,et al.  Apoptosis in human acute myocardial infarction. , 1997, Circulation.

[23]  Richard B. Thompson,et al.  A novel protective effect of erythropoietin in the infarcted heart. , 2003, The Journal of clinical investigation.

[24]  I. Macdougall,et al.  Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  R. Carlini,et al.  Recombinant human erythropoietin stimulates angiogenesis in vitro. , 1995, Kidney international.

[26]  E. Lakatta,et al.  Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Donnelly,et al.  Why is erythropoietin made in the kidney? The kidney functions as a critmeter. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  A. Barrientos,et al.  Cardiovascular effects of recombinant human erythropoietin in predialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Kenneth Maiese,et al.  Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases , 2002, Circulation.

[30]  G. Condorelli,et al.  Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. , 1994, The American journal of cardiology.

[31]  B. Leyland-Jones.  Evidence for erythropoietin as a molecular targeting agent. , 2002, Seminars in oncology.

[32]  Stuart A. Lipton,et al.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.

[33]  J. Adamson,et al.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.

[34]  M. Safar,et al.  Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. , 1989, Kidney international.

[35]  C. Bozzini,et al.  Erythropoietin improves cardiac contractility in post‐hypoxic mice , 2003, British journal of haematology.

[36]  J. Adamson,et al.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.

[37]  D. Fliser,et al.  Erythropoietin regulates endothelial progenitor cells. , 2004, Blood.

[38]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[39]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[40]  B. Ebert,et al.  Regulation of the erythropoietin gene. , 1999, Blood.

[41]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[42]  Harlan M Krumholz,et al.  The prognostic importance of anemia in patients with heart failure. , 2003, The American journal of medicine.

[43]  I. Macdougall,et al.  Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  Pietro Ghezzi,et al.  Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[46]  T. Honkanen,et al.  High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril , 1989, Journal of internal medicine.

[47]  E. Friedman,et al.  Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. , 1992, American heart journal.

[48]  L. Lund,et al.  Hemodilution Is Common in Patients With Advanced Heart Failure , 2003, Circulation.

[49]  Adesh K. Jain,et al.  Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. , 1990, Blood.

[50]  A. Levin,et al.  Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. , 2000, Kidney international.

[51]  P. Ghezzi,et al.  Neuroprotective properties of epoetin alfa. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  D. Schwartz,et al.  Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. , 2003, The Israel Medical Association journal : IMAJ.

[53]  C. Lang,et al.  Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.

[54]  A. Lassar,et al.  Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. , 2003, Developmental biology.